DDF's New CSO Will Get Dementia Discovery 'Out Of A Rut'
This article was originally published in Scrip
The UK-based Dementia Discovery Fund's first investment was a bit of let-down for academic scientists as it went to an established US biotech company. But this could all change with the appointment of chief scientific officer Dr Tetsuyuki Maruyama (formerly Paul Chapman), who will start his new job in April. Despite a strong pharma executive background, his origins as an academic neuroscientist ensure he knows exactly what is being expected of him by the academic masses.
You may also be interested in...
The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.